Podcast appearances and mentions of michael okun

Parkinson's disease is rising faster than ever before — with 90,000 new U.S. cases every year. But what if it's not just bad luck, aging, or genetics? In this powerful conversation (watch HERE on YouTube), one of the world's leading neurologists, Dr. Michael Okun, reveals shocking truths from the new book The Parkinson's PLAN, co-authored with Dr. Ray Dorsey:  ☠️ The hidden toxins in our air, water, and food that are driving the disease

In this episode, Lyell K. Jones Jr, MD, FAAN, speaks with Michael S. Okun, MD, FAAN, who served as the guest editor of the August 2025 Movement Disorders issue. They provide a preview of the issue, which publishes on August 1, 2025. Dr. Jones is the editor-in-chief of Continuum: Lifelong Learning in Neurology® and is a professor of neurology at Mayo Clinic in Rochester, Minnesota. Dr. Okun is the director at Norman Fixel Institute for Neurological Diseases and distinguished professor of neurology at University of Florida in Gainesville, Florida. Additional Resources Read the issue: continuum.aan.com Subscribe to Continuum®: shop.lww.com/Continuum Continuum® Aloud (verbatim audio-book style recordings of articles available only to Continuum® subscribers): continpub.com/Aloud More about the American Academy of Neurology: aan.com Social Media facebook.com/continuumcme @ContinuumAAN Host: @LyellJ Guest: @MichaelOkun Full episode transcript available here: Dr Jones: Our ability to move through the world is one of the essential functions of our nervous system. Gross movements like walking ranging down to fine movements with our eyes and our hands, our ability to create and coordinate movement is something many of us take for granted. So what do we do when those movements stop working as we intend? Today I have the opportunity to speak with one of the world's leading experts on movement disorders, Dr Michael Okun, about the latest issue of Continuum on Movement Disorders. Dr Jones: This is Dr Lyell Jones, Editor-in-Chief of Continuum. Thank you for listening to Continuum Audio. Be sure to visit the links in the episode notes for information about subscribing to the journal, listening to verbatim recordings of the articles, and exclusive access to interviews not featured on the podcast. Dr Jones: This is Dr Lyle Jones, Editor-in-Chief of Continuum: Lifelong Learning in Neurology. Today, I'm interviewing Dr Michael Okun, who is Continuum's guest editor for our latest issue on movement disorders. Dr Okun is the Adelaide Lackner Distinguished Professor of Neurology at the University of Florida in Gainesville, where he's also the director of the Norman Fixel Institute for Neurological Diseases. Dr Okun, welcome, and thank you for joining us today. Why don't you introduce yourselves to our listeners?  Dr Okun: It's great to be here today. And I'm a neurologist. Everybody who knows me knows I'm pretty simple. I believe the patient's the sun and we should always orbit around the person with disease, and so that's how I look at my practice. And I know we always participate in a lot of research, and I've got a research lab and all those things. But to me, it's always the patients and the families first. So, it'll be great to have that discussion today.  Dr Jones: Yeah, thank you for that, Dr Oaken. Obviously, movement disorders is a huge part of our field of neurology. There are many highly prevalent conditions that fit into this category that most of our listeners will be familiar with: idiopathic Parkinson's disease, essential tremor, tic disorders and so on. And having worked with trainees for a long time, it's one of the areas that I see a lot of trainees gravitate to movement disorders. And I think it's in part because of the prevalence; I think it's in part because of the diversity of the specialty with treatment options and DBS and Botox. But it's also the centrality of the neurologic exam, right? That's- the clinical examination of the patient is so fundamental. And we'll cover a lot of topics today with some questions that I have for you about biomarkers and new developments in the field. But is that your sense too, that people are drawn to just the old-fashioned, essential focus on the neurologic encounter and the neurologic exam? Dr Okun: I believe that is one of the draws to the field of movement. I think that you have neurologists from all over the world that are really interested and fascinated with what things look like. And when you see something that's a little bit, you know, off the normal road or off the normal beaten path… and we are always curious. And so, I got into movement disorders, I think, accidentally; I think even as a child, I was looking at people who had abnormal movements and tremors and I was very fascinated as to why those things happened and what's going on in the brain. And, you know, what are the symptoms and the signs. And then later on, even as my own career developed, that black bag was so great as a neurologist. I mean, it makes us so much more powerful than any of the other clinicians---at least in my biased opinion---out on the wards and out in the clinic. And, you know, knowing the signs and the symptoms, knowing how to do a neurological examination and really walking through the phenomenology, what people look like, you know, which is different than the geno- you know, the genotypes, what the genes are. What people look like is so much more important as clinicians. And so, I think that movement disorders is just the specialty for that, at least in my opinion. Dr Jones: And it helps bring it back to the patient. And that's something that I saw coming through the articles in this issue. And let's get right to it. You've had a chance to review all these articles on all these different topics across the entire field of movement disorders. As you look at that survey of the field, Dr Okun, what do you think is the most exciting recent development for patients with movement disorders?  Dr Okun: I think that when you look across all of the different specialties, what you're seeing is a shift. And the shift is that, you know, a lot of people used to talk in our generation about neurology being one of these “diagnose and adios” specialties. You make the diagnosis and there's nothing that you can do, you know, about these diseases. And boy, that has changed. I mean, we have really blown it out of the water. And when you look at the topics and what people are writing about now and the Continuum issue, and we compare that the last several Continuum issues on movement disorders, we just keep accumulating a knowledge base about what these things look like and how we can treat them. And when we start thinking about, you know, all of the emergence of the autoimmune disorders and identifying the right one and getting something that's quite treatable. Back in my day, and in your day, Lyle, we saw these things and we didn't know what they were. And now we have antibodies, now we can identify them, we can pin them down, and we can treat many of them and really change people's lives. And so, I'm really impressed at what I see in changes in identification of autoimmune disorders, of channelopathies and some of the more rare things, but I'm also impressed with just the fundamental principles of how we're teaching people to be better clinicians in diseases like Parkinson's, Huntington's, ataxia, and Tourette. And so, my enthusiasm for this issue of Continuum is both on, you know, the cutting edge of what we're seeing based on the identification on our exams, what we can do for these people, but also the emergence of how we're shifting and providing much better care across a continuum for folks with basal ganglia diseases. Dr Jones: Yeah, I appreciate that perspective, Dr Okun. One of the common themes that I saw in the issue was with these new developments, right, when you have new tools like new diagnostic biomarker tools, is the question of if and when and how to integrate those into daily clinical practice, right? So, we've had imaging biomarkers for a while, DAT scans, etc. For patients with idiopathic Parkinson disease, one of the things that I hear a lot of discussion and controversy about are the seed amplification assays as diagnostic biomarkers. What can you tell us about those? Are those ready for routine clinical use yet?  Dr Okun: I think the main bottom-line point for folks that are out there trying to practice neurology, either in general clinics or even in specialty clinics, is to know that there is this movement toward, can we biologically classify a disease? One of the things that has, you know, really accelerated that effort has been the development of these seed amplification assays, which---in short for people who are listening---are basically, we “shake and bake” these things. You know? We shake them for like 20 hours and we use these prionlike proteins, and we learn from diseases like prion disease how to kind of tag these things and then see, do they have degenerative properties? And in the case of Parkinson's disease, we're able to do this with synuclein. That is the idea of a seed amplification assay. We're able to use this to see, hey, is there synuclein present or not in this sample? And people are looking at things like cerebrospinal fluid, they're looking at things like blood and saliva, and they're finding it. The challenge here is that, remember- and one of the things that's great about this issue of Continuum is, remember, there are a whole bunch of different synucleinopathies. So, Dr Jones, it isn't just Parkinson's disease. So, you've got Parkinson's disease, you've got Lewy body, you know, and dementia with Lewy bodies. You've got, you know, multiple system atrophy is within that synucleinopathy, you know, group primary autonomic failure… so not just Parkinson's disease. And so, I think we have to tap the brakes as clinicians and just say, we are where we are. We are moving in that direction. And remember that a seed amplification assay gives you some information, but it doesn't give you all the information. It doesn't forgive you looking at a person over time, examining them in your clinic, seeing how they progress, seeing their response to dopamine- and by the way, several of these genes that are associated with Parkinson; and there's, you know, less than 20% of Parkinson is genetic, but several of these genes, in a solid third---and in some cases, in some series, even more---miss the synuclein assay, misses, you know, the presence of a disease like Parkinson's disease. And so, we have to be careful in how we interpret it. And I think we're more likely to see over time a gemish: we're going to smush together all this information. We're going to get better with MRIs. And so, we're actually doing much better with MRIs and AI-based intelligence. We've got DAT scans, we've got synuclein assays. But more than anything, everybody listening out there, you can still examine the person and examine them over time and see how they do over time and see how they do with dopamine. And that is still a really, really solid way to do this. The synuclein assays are probably going to be ready for prime time more in choosing and enriching clinical trials populations first. And you know, we're probably 5, 10 years behind where Alzheimer's is right now. So, we'll get there at some point, but it's not going to be a silver bullet. I think we're looking at these are going to be things that are going to be interpreted in the context for a clinician of our examination and in the context of where the field is and what you're trying to use the information for. Dr Jones: Thank you for that. And I think that's the general gestalt I got from the articles and what I hear from my colleagues. And I think we've seen this in other domains of neurology, right? We have the specificity and sensitivity issues with the biomarkers, but we also have the high prevalence of copathology, right? People can have multiple different neurodegenerative problems, and I think it gets back to that clinical context, like you said, following the patient longitudinally. That was a theme that came out in the idiopathic Parkinson disease article. And while we're on Parkinson disease, you know, the first description of that was what, more than two hundred years ago. And I think we're still thinking about the pathophysiology of that disorder. We understand risk factors, and I think many of our listeners would be familiar with those. But as far as the actual cause, you know, there's been discussion in recent years about, is there a role of the gut microbiome? Is this a prionopathic disorder? What's your take on all of that?  Dr Okun: Yeah, so it's a great question. It's a super-hot area right now of Parkinson. And I kind of take this, you know, apart in a couple of different ways. First of all, when we think about Parkinson disease, we have to think upstream. Like, what are the cause and causes? Okay? So, Parkinson is not one disease, okay? And even within the genes, there's a bunch of different genes that cause it. But then we have to look and say, well, if that's less than 20% depending on who's counting, then 80% don't have a single piece of DNA that's closely associated with this syndrome. And so, what are we missing with environment and other factors? We need to understand not what happens at the end of the process, not necessarily when synuclein is clumping- and by the way, there's a lot of synuclein in the brains normally, and there's a lot of Tau in people's brains who have Parkinson as well. We don't know what we don't know, Dr Jones. And so when we begin to think about this disease, we've got to look upstream. We've got to start to think, where do things really start? Okay? We've got to stop looking at it as probably a single disease or disorder, and it's a circuit disorder. And then as we begin to develop and follow people along that pathway and continuum, we're going to realize that it's not a one-size-fits-all equation when we're trying to look at Parkinson. By the way, for people listening, we only spend two to three cents out of every dollar on prevention. Wouldn't prevention be the best cure, right? Like, if we were thinking about this disease. And so that's something that we should be, you know, thinking about. And then the other is the Global Burden of Disease study. You know, when we wrote about this in a book called Ending Parkinson's Disease, it looked like Parkinson's was going to double by 2035. The new numbers tell us it's almost double to the level that we expected in 2035 in this last series of numbers. So, it's actually growing much faster. We have to ask why? Why is it growing faster? And then we have lots of folks, and even within these issues here within Continuum, people are beginning to talk about maybe these environmental things that might be blind spots. Is it starting in our nose? Is it starting in our gut? And then we get to the gut question. And the gut question is, if we look at the microbiomes of people with Parkinson, there does seem to be, in a group of folks with Parkinson, a Parkinson microbiome. Not in everyone, but if you look at it in composite, there seems to be some clues there. We see changes in Lactobacillus, we see some bacteria going up that are good, some bacteria going down, you know, that are bad. And we see flipping around, and that can change as we put people on probiotics and we try to do fecal microbiota transplantations- which, by the way, the data so far has not been positive in Parkinson's. Doesn't mean we might not get there at some point, but I think the main point here is that as we move into the AI generation, there are just millions and millions and millions of organisms within your gut. And it's going to take more than just our eyes and just our regular arithmetic. You and I probably know how to do arithmetic really well, but this is, like, going to be a much bigger problem for computers that are way smarter than our brains to start to look and say, well, we see the bacteria is up here. That's a good bacteria, that's a good thing or it's down with this bacteria or this phage or there's a relationship or proportion that's changing. And so, we're not quite there. And so, I always tell people---and you know, we talk about the sum in the issue---microbiomes aren't quite ready for prime time yet. And so be careful, because you could tweak the system and you might actually end up worse than before you started. So, we don't know what we don't know on this issue.  Dr Jones: And that's a great point. And one of the themes they're reading between the lines is, we will continue to work on understanding the bio-pathophysiology, but we can't wait until that day to start managing the risk factors and treating patients, which I think is a good point. And if we pivot to treatment here a little bit, you know, one of the exciting areas of movement disorders---and really neurology broadly, I think movement disorders has led the field in many ways---is bioelectronic therapy, or what one of my colleagues taught me is “electroceutical therapy”, which I think is a wonderful term. Dr Okun, when our listeners are hearing about the latest in deep brain stimulation in patients who have movement disorders, what should they know? What are the latest developments in that area with devices? Dr Okun: Yeah. So, they should know that things are moving rapidly in the field of putting electricity into the brain. And we're way past the era where we thought putting a little bit of electricity was snake oil. We know we can actually drive these circuits, and we know that many of these disorders---and actually, probably all of the disorders within this issue of Continuum---are all circuit disorders. And so, you can drive the circuit by modulating the circuit. And it's turned out to be quite robust with therapies like deep brain stimulation. Now, we're seeing uses of deep brain stimulation across multiple of these disorders now. So, for example, you may think of it in Parkinson's disease, but now we're also seeing people use it to help in cases where you need to palliate very severe and bothersome chorea and Huntington's disease, we're seeing it move along in Tourette syndrome. We of course have seen this for various hyperkinetic disorders and dystonias. And so, the main thing for clinicians to realize when dealing with neuromodulation is, take a deep breath because it can be overwhelming. We have a lot of different devices in the marketplace and no matter how many different devices we have in the marketplace, the most important thing is that we get the leads. You know, where we're stimulating into the right location. It's like real estate: location, location, location, whether you've got a lead that can steer left, right, up, down and do all of these things. Second, if you're feeling overwhelmed because there are so many devices and so many settings, especially as we put these leads in and they have all sorts of different, you know, nodes on them and you can steer this way and that way, you are not alone. Everybody is feeling that way now. And we're beginning to see AI solutions to that that are going to merge together with imaging, and then we're moving toward an era of, you know, should I say things like robotic programming, where it's going to be actually so complicated as we move forward that we're going to have to automate these systems. There's no way to get this and scale this for all of the locales within the United States, but within the entire world of people that need these types of devices and these therapies. And so, it's moving rapidly. It's overwhelming. The most important thing is choosing the right person. Okay? For this, with multidisciplinary teams, getting the lead in the right place. And then all these other little bells and whistles, they're like sculpting. So, if you think of a sculpture, you kind of get that sculpture almost there. You know, those little adds are helping to maybe make the eyes come out a little more or the facial expression a little bit better. There's little bits of sculpting. But if you're feeling overwhelmed by it, everybody is. And then also remember that we're starting to move towards some trials here that are in their early stages. And a lot of times when we start, we need more failures to get to our successes. So, we're seeing trials of people looking at, like, oligo therapies and protein therapies. We're seeing CRISPR gene therapies in the laboratory. And we should have a zero tolerance for errors with CRISPR, okay? we still have issues with CRISPR in the laboratory and which ones we apply it to and with animals. But it's still pretty exciting when we're starting to see some of these therapies move forward. We're going to see gene therapies, and then the other thing we're going to see are nano-therapies. And remember, smaller can be better. It can slip across the blood brain barrier, you have very good surface area-to-volume ratios, and we can uncage drugs by shining things like focused ultrasound beams or magnets or heat onto these particles to turn them on or off. And so, we're seeing a great change in the field there. And then also, I should mention: pumps are coming and they're here. We're getting pumps like we have for diabetes and neurology. It's very exciting. It's going to be overwhelming as everybody tries to learn how to do this. So again, if you're feeling overwhelmed, so am I. Okay? But you know, pumps underneath the skin for dopamine, pumps underneath the skin for apomorphine. And that may apply to other disorders and not just Parkinson as we move along, what we put into those therapies. So, we're seeing that age come forward. And then making lesions from outside the brain with focused ultrasound, we're starting to get better at that. Precision is less coming from outside the brain; complications are also less. And as we learn how to do that better, that also can provide more options for folks. So, a lot of things to read about in this issue of Continuum and a lot of really interesting and beyond, I would say, you know, the horizon as to where we're headed.  Dr Jones: Thank you for that. And it is a lot. It can be overwhelming, which I guess is maybe a good reason to read the issue, right? I think that's a great place to end and encourage our listeners to pick up the issue. And Dr Okun, I want to thank you for joining us today. Thank you for such a great discussion on movement disorders. I learned a lot. I'm sure our listeners will as well, given the importance of the topic, your leadership in the field over many years. I'm grateful that you have put this issue together. So, thank you. And you're a busy person. I don't know how we talked you into doing this, but I'm really glad that we did.  Dr Okun: Well, it's been my honor. And I just want to point out that the whole authorship panel that agreed to write these articles, they did all the work. I'm just a talking head here, you know, telling you what they did, but they're writing, and the people that are in the field are really, you know, leading and helping us to understand, and have really put it together in a way that's kind of helped us to be better clinicians and to impact more lives. So, I want to thank the group of authors, and thank you, Dr Jones. Dr Jones: Again, we've been speaking with Dr Michael Okun, guest editor of Continuum's most recent issue on movement disorders. Please check it out. And thank you to our listeners for joining today. Dr Monteith: This is Dr Teshamae Monteith, Associate Editor of Continuum Audio. If you've enjoyed this episode, you'll love the journal, which is full of in-depth and clinically relevant information important for neurology practitioners. Use the link in the episode notes to learn more and subscribe. Thank you for listening to Continuum Audio.

To subscribe to our podcast and YouTube channel visit: https://www.youtube.com/@davisphinneyfdn/podcasts In this episode of the Parkinson's Podcast, Executive Director Polly Dawkins speaks with Dr. Ray Dorsey and Dr. Michael Okun about their forthcoming book, "The Parkinson's Plan: A New Path to Prevention and Treatment," set for release on August 19, 2025. Framed around the acronym PLAN—Prevent, Learn, Amplify, Navigate—the book shares compelling stories from the Parkinson's community and outlines a bold roadmap toward prevention and proactive care. Listen in as the authors discuss what inspired them to write the book and the actions we can take now to help create a world without Parkinson's. Learn more about "The Parkinson's Plan: A New Path to Prevention and Treatment" here: https://pdplan.org To learn more about the Davis Phinney Foundation for Parkinson's visit: https://dpf.org Season 6 Episode 10

To subscribe to our podcast and YouTube channel visit: https://www.youtube.com/@davisphinneyfdn/podcasts In this episode, we're sharing an excerpt from our May 2025 Live Well Today webinar about Emerging Therapies for Parkinson's, which features Dr. Soania Mathur and Dr. Michael Okun. In this excerpt, Dr. Mathur and Dr. Okun discuss three emerging treatments for Parkinson's that are designed for continuous under-the-skin infusion. These treatments have all been found to increase the amount of time Parkinson's symptoms are well managed throughout the day. You can learn more about these and other emerging therapies by watching the entire May 2025 Live Well Today webinar recording. Watch the full webinar here: https://youtu.be/zqdXgoyVHT8 Medications discussed in this episode: Vyalev, the first 24-hour infusion of foslevodopa and foscarbidopa: https://davisphinneyfoundation.org/continuous-infusion-levodopa-approved-usa/ ONAPGO, an apomorphine infusion that offers rapid relief from OFF episodes: https://davisphinneyfoundation.org/continuous-infusion-apomorphine-approved/ And NeuroDerm ND0612, an investigational levodopa/carbidopa infusion, now in late-stage trials: https://neuroderm.com/our-solution/about/what-is-nd0612/ Season 6 Episode 9

Parkinson's Disease has long been a clinical diagnosis. But recently, there have been proposals to redefine the disease based on biomarkers of alpha-synucleinopathy and dopaminergic dysfunction. A similar shift has already occurred in Alzheimer disease, with the “amyloid, tau, and neurodegeneration,” or ATN, classification system.    Our guest today, Michael Okun, is is Professor of Neurology and Director of the Norman Fixel Institute for Neurological Diseases at the University of Florida and medical advisor for the Parkinson's Foundation. He co-authored an op-ed in JAMA last summer in JAMA arguing that there would be benefits to a biological definition of Parkinson's - but there would also be risks. He'll unpack both sides of this debate today with Dr. Christine Doss Esper, Associate Professor of Neurology at Emory University. Series 6, Episode  5     Featuring: Guest: Dr. Michael Okun, is Professor of Neurology and Director of the Norman Fixel Institute for Neurological Diseases at the University of Florida and medical advisor for the Parkinson's Foundation Interviewer: Dr. Christine Doss Esper, Associate Professor of Neurology at Emory University Disclosures: None

In this episode, Brain & Life Podcast co-hosts Dr. Daniel Correa and Dr. Katy Peters answer some listener-submitted questions. Then, Dr. Correa is then joined by Dr. Michael Okun, co-director of the Center for Movement Disorders and Neurorestoration, and the Adelaide Lackner Professor of Neurology at the University of Florida. Dr. Okun sheds light on the increasing rates of Parkinson's disease diagnosis in our communities, environmental factors that may contribute to the disease, and important considerations for those diagnosed with Parkinson's.   Additional Resources Parkinson Secrets Skin Problems May Be Early Signs of a Neurologic Condition Factors That May Increase the Risk of Parkinson's Disease Parkinson's Disease Won't Extinguish This Firefighter's Passion   Other Brain & Life Podcast Episodes Ed Begley Jr. on Utilizing a Healthy Lifestyle to Thrive with Parkinson's Disease How American Ninja Warrior Jimmy Choi Rose Above Parkinson's Comedy and Courage: Comedian Richard Lewis on Living with Parkinson's Disease   We want to hear from you! Have a question or want to hear a topic featured on the Brain & Life Podcast? ·       Record a voicemail at 612-928-6206 ·       Email us at BLpodcast@brainandlife.org   Social Media:  Dr. Michael Okun @michaelokun @fixelinstitute Hosts: Dr. Daniel Correa @neurodrcorrea; Dr. Katy Peters @KatyPetersMDPhD

Mike interviews Dr. Michael Okun on Parkinson's Disease. Michael Okun, MD, is a board-certified neurologist, movement disorders specialist, neuroscientist, and author who practices with the philosophy that ‘the patient is the sun' and should be at the center of all care decisions. He co-founded and co-directs the internationally renowned Norman Fixel Institute for Neurological Diseases with neurosurgeon partner and friend Kelly Foote, MD. Since 2006, he has served as both the Medical Director and, most recently, the Medical Advisor for the Parkinson's Foundation. Michael Okun Book: https://amzn.to/3Vj5GHW Website: https://neurology.ufl.edu/profile/okun-michael/ --- Support this podcast: https://podcasters.spotify.com/pod/show/bobandbrad/support

In this episode of the I Love Neuro podcast, hosts Erin Gallardo and Claire McLean discuss important updates and research related to Parkinson's disease. They used neurologist Dr. Michael Okun's Instagram account as inspiration for the recent research to discuss.  The first article discussed is titled End-of-life Health Care Service Use and Cost Among Medicare Decendents With Neurodegerative Diseases. The discussion highlights the high healthcare costs and lack of planning for end-of-life care in neurodegenerative diseases like Parkinson's. The article emphasizes the importance of involving neurologists and having a comprehensive care plan to improve outcomes, and we discuss what that might look like. The second article discussed is titled Pain Fluctuation in Parkinson's Disease and their Association with Motor and Non-Motor Fluctuations with an interesting finding about the type of pain people with PD typically experience, when they experience and our theories about why. Pain management is an expensive and often frustrating industry, so this is an important topic! Find the article here: End-of-life Health Care Service Use and Cost Among Medicare Decendents With Neurodegerative Diseases Find the article here: Pain Fluctuation in Parkinson's Disease and their Association with Motor and Non-Motor Fluctuations Follow Dr. Michael Okun here for PD research updates!

Parkinson's disease (PD) is a “clinical” diagnosis, based on a person's medical history, symptoms, and physical exam. Although certain laboratory or imaging tests can be helpful in reaching a diagnosis, no single test can confirm PD. Among the tests currently used to support a PD diagnosis, or to rule out other conditions that can mimic PD, are magnetic resonance imaging (MRI) of the brain, the dopamine transporter scan (DaTscan) to look at how dopamine is transported in certain areas of the brain, Syn-One, or skin biopsies, and blood work. Sometimes, a PD diagnosis is straightforward based on the presence of certain symptoms, but in other cases, it may take a number of clinic visits to make a definitive diagnosis. The best way to ensure a correct diagnosis of PD, or a similar condition, is to see a neurologist specializing in movement disorders. One of the leading Parkinson's specialists is Dr. Michael Okun, National Medical Advisor for the Parkinson's Foundation and Director of the Fixel Institute for Neurological Diseases at the University of Florida in Gainesville. In this podcast episode, he explains some of the current tools for making a Parkinson's diagnosis, how they are used, and some of their limitations.

From 18th century London to the promise of a global cure: the 200-year history of Parkinson's disease. Parkinson's, a neurodegenerative disorder most commonly characterized by tremors and other motor symptoms, is so complex, many medical professionals are starting to classify it as a group of diseases, rather than a single disease. In this episode, we explain those complexities, including: • The motor symptoms (e.g. cogwheel rigidity, bradykinesia) and non-motor symptoms (e.g. depression, sleep disorders) • How the industrial revolution may have brought about environmental factors which contribute to Parkinson's • The differences and similarities between Parkinson's and other neurodegenerative diseases, like Alzheimer's • How Parkinson's manifests in our brains • Why one nurse was able to detect Parkinson's through smell • The neurogenetics of Parkinson's, and the ethical quandaries of evolving genetic technology • Why lifestyle — nutrition, exercise, etc. — is so key to preventing and managing Parkinson's Joining us for this extensive conversation are three incredible guests: • Dr. Rachel Dolhun, Senior Vice President of Medical Communications at The Michael J. Fox Foundation for Parkinson's Research • Dr. Michael Okun, evolutionary biologist, movement disorders specialist, and Director of the Norman Fixel Institute for Neurological Diseases • Dr. Matthew Farrer, neurogenetics expert and Professor Of Neurology at the University of Florida ‘Your Brain On' is hosted by neurologists, scientists and public health advocates Ayesha and Dean Sherzai. Drs. Ayesha and Dean are now welcoming patients via the Brain Health Institute: https://brainhealthinstitute.com/ ‘Your Brain On... Parkinson's' • SEASON 3 • EPISODE 1 (SEASON 3 DEBUT) ————— LINKS   Dr. Rachel Dolhun: At the Michael J. Fox Foundation: https://www.michaeljfox.org/bio/rachel-dolhun-md-dipablm  ‘Ask the MD' series: https://www.michaeljfox.org/ask-md  The Michael J. Fox Foundation on YouTube: https://www.youtube.com/@michaeljfoxfoundation/videos  Dr. Michael Okun: At the University of Florida: https://neurology.ufl.edu/profile/okun-michael/  The book ‘Ending Parkinson's Disease': https://endingpd.org/  The Norman Fixel Institute: https://fixel.ufhealth.org/   Dr. Matthew Farrer: At the University of Florida: https://neurology.ufl.edu/profile/farrer-matthew/ ————— References: Bloem, B. R., Okun, M. S., & Klein, C. (2021). Parkinson's disease. The Lancet, 397(10291), 2284-2303. Morris, H. R., Spillantini, M. G., Sue, C. M., & Williams-Gray, C. H. (2024). The pathogenesis of Parkinson's disease. The Lancet, 403(10423), 293-304. Dorsey, E., Sherer, T., Okun, M. S., & Bloem, B. R. (2018). The emerging evidence of the Parkinson pandemic. Journal of Parkinson's disease, 8(s1), S3-S8. Dorsey, E. R., Okun, M. S., & Tanner, C. M. (2021). Bad Air and Parkinson Disease—The Fog May Be Lifting. JAMA neurology, 78(7), 793-795. Tsalenchuk, M., Gentleman, S. M., & Marzi, S. J. (2023). Linking environmental risk factors with epigenetic mechanisms in Parkinson's disease. npj Parkinson's Disease, 9(1), 123. Reynoso, A., Torricelli, R., Jacobs, B. M., Shi, J., Aslibekyan, S., Norcliffe‐Kaufmann, L., ... & Heilbron, K. (2024). Gene–Environment Interactions for Parkinson's Disease. Annals of Neurology, 95(4), 677-687. Golsorkhi, M., Sherzai, A., & Dashtipour, K. The Influence of Lifestyle on Parkinson's Disease Management. In Lifestyle Medicine, Fourth Edition (pp. 919-924). CRC Press. Sherzai, A. Z., Tagliati, M., Park, K., Pezeshkian, S., & Sherzai, D. (2016). Micronutrients and risk of Parkinson's disease: a systematic review. Gerontology and geriatric medicine, 2, 2333721416644286. ————— FOLLOW US  Join the NEURO Academy: NEUROacademy.com  Instagram: @thebraindocs Website: TheBrainDocs.com More info and episodes: TheBrainDocs.com/Podcast

Today on Meldon Law & Friends, we are joined first by Dr. Michael Okun, the chair of the UF Health Department of Neurology and the Executive Director of Norman Fixel Institute for Neurological Diseases at UF Health. He is the world's leading expert in Parkinson's disease and dystonia and has been behind the research for Tyler's Hope for over 15 years. He was also one of Muhammad Ali's doctors. Our second guests are Lizzie Jenkins of the Real Rosewood Foundation and Melody Vaughn, owner of Melody Vaughn Interiors. Lizzie Jenkins and Melody Vaughn are working on rebuilding and remodeling some of Rosewood, Florida. They will tell us more about the Rosewood Massacre, why they are rebuilding Rosewood, and more about Melody Vaughn Interiors.

For decades, researchers, clinicians, and industry professionals have continued to study and optimize deep brain stimulation (DBS) with the goal of providing the best possible personalized treatment for Parkinson's disease (PD) and other neurological conditions. In this episode, Dr. Michael Okun joins us to discuss his research and some of the recent advances in deep brain stimulation and other areas. He draws from his extensive research and clinical experience applying DBS and neuromodulation therapies for patients with PD, Tourette syndrome, tic disorders, dystonia, essential tremor, and obsessive-compulsive disorder. Michael is co-founder and co-director of the Norman Fixel Institute for Neurological Diseases at the University of Florida, as well as Medical Advisor for the Parkinson's Foundation. He is a board-certified neurologist, movement disorders specialist, neuroscientist, author, and an expert on deep brain stimulation and neuromodulation for movement disorders. This podcast is geared toward researchers and clinicians. If you live with Parkinson's or have a friend or family member with PD, listen to The Michael J. Fox Foundation Parkinson's Podcast. Hear from scientists, doctors and people with Parkinson's on different aspects of life with the disease as well as research toward treatment breakthroughs at https://www.michaeljfox.org/podcasts.

For decades, researchers, clinicians, and industry professionals have continued to study and optimize deep brain stimulation (DBS) with the goal of providing the best possible personalized treatment for Parkinson's disease (PD) and other neurological conditions. In this episode, Dr. Michael Okun joins us to discuss his research and some of the recent advances in deep brain stimulation and other areas. He draws from his extensive research and clinical experience applying DBS and neuromodulation therapies for patients with PD, Tourette syndrome, tic disorders, dystonia, essential tremor, and obsessive-compulsive disorder. Michael is co-founder and co-director of the Norman Fixel Institute for Neurological Diseases at the University of Florida, as well as Medical Advisor for the Parkinson's Foundation. He is a board-certified neurologist, movement disorders specialist, neuroscientist, author, and an expert on deep brain stimulation and neuromodulation for movement disorders. This podcast is geared toward researchers and clinicians. If you live with Parkinson's or have a friend or family member with PD, listen to The Michael J. Fox Foundation Parkinson's Podcast. Hear from scientists, doctors and people with Parkinson's on different aspects of life with the disease as well as research toward treatment breakthroughs at https://www.michaeljfox.org/podcasts.

In this episode, Dr. Soania Mathur interviews Dr. Michael Okun to discuss the latest therapies for Parkinson's, including RT-QUIC (Parkinson's biomarker), subcutaneous dopamine pumps, vibrating gloves, rescue medications, DBS, and more.  Dr. Mathur and Dr. Okun discuss: New discoveries in diagnosing Parkinson's What do certain biological markers mean for diagnosis? What's new on the horizon for Parkinson's treatments? The subcutaneous delivery of dopamine replacement Transdermal treatment Microbiome in Parkinson's Vibration therapy The importance of individualized care plans How to sort through all the information about Parkinson's and more. We hope you enjoy!

Are you challenged with non motor Parkinson's symptoms?  Do you experience fatigue and sleep disruptions? Dr. Michael Okun discusses the management of these symptoms and more.Please join me as I speak with world Parkinson's leader, Dr. Michael Okun.  Dr. Okun is a board-certified neurologist, movement disorders specialist, neuroscientist and author who practices with the philosophy that ‘the patient is the sun' and should be at the center of all care decisions.Dr. Okun co-founded and co-directs the internationally renowned Norman Fixel Institute for Neurological Diseases with his neurosurgeon partner and friend, Kelly Foote, MD. Since 2006.  He also serves as the Medical Advisor for the Parkinson's Foundation.In addition, Dr. Okun has authored 14 books related to living a full life with neurological disorders including Parkinson's Treatment: 10 Secrets to a Happier Life and Ending Parkinson's Disease.Dr. Okun shares his insight and perspective on how to best manage Parkinson's disease. 

This week, Dr. Audrey Nath speaks with David Begnaud, lead national correspondent for CBS Mornings, about his experience of being diagnosed with Tourette syndrome when he was a child. David shares what it was like to navigate tics at a young age, how he learned to embrace them as an adult, and how he is raising awareness to fight the stigma that can accompany the neurologic condition. Next, Dr. Nath sits down with Dr. Michael Okun, executive director of the Norman Fixel Institute for Neurological Diseases and professor of neurology at University of Florida Health. Dr. Okun explains what happens in the brain of someone living with Tourette syndrome, various ways the condition can be treated, and what he is hopeful for in the future of therapy development. [We apologize for some audio issues during this episode, but we feel this is excellent and important information for the community and to raise awareness about Tourette syndrome.] Additional Resources: Tourette syndrome resources from the Brain & Life website and magazine What is Tourette syndrome Tourette Syndrome Association  We want to hear from you! Have a question or want to hear a topic featured on the Brain & Life Podcast? Record a voicemail at 612-928-6206, or email us at BLpodcast@brainandlife.org. Social Media:   Guest: David Begnaud @DavidBegnaud (Twitter & Instagram); Dr. Michael Okun (@MichaelOkun) Hosts: Dr. Daniel Correa @neurodrcorrea; Dr. Audrey Nath @AudreyNathMDPhD

Please join me as I speak with world Parkinson's leader, Dr. Michael Okun.  Dr. Okun is a board-certified neurologist, movement disorders specialist, neuroscientist and author who practices with the philosophy that ‘the patient is the sun' and should be at the center of all care decisions.Dr. Okun co-founded and co-directs the internationally renowned Norman Fixel Institute for Neurological Diseases with his neurosurgeon partner and friend, Kelly Foote, MD. Since 2006.  He also serves as the Medical Advisor for the Parkinson's Foundation.In addition, Dr. Okun has authored 14 books related to living a full life with neurological disorders including Parkinson's Treatment: 10 Secrets to a Happier Life and Ending Parkinson's Disease.Dr. Okun shares his insight and perspective on how to best manage Parkinson's disease.  

In today's episode of the PWP Dr. Hyland discusses the DaT scan; what it is and whether or not it is worth your time. It may not be all DAT... Sorry I just couldn't resist. Dr. Michael Okun, MD discussed this topic right after the test was FDA approved back in 2011. You can find his article from which some of his statements were paraphrased here.  Please support this podcast and our endeavors by becoming a co-producer of the show! Sign up as a Patreon supporter here at https://www.patreon.com/pdwarriors Also, you can leave a one time tip in our virtual tip jar at: https://paypal.me/hylandptw

In the last episode focused on peer reviews, Dr. Michael Okun discusses historical perspectives and future directions of the peer review process.

The tenth DBS Think Tank is about to happen in Gainesville, Florida next month – so it's timely to talk with the masterminds behind it: Michael Okun and Kelly Foote need no introduction in the field & represent a role-model power-couple of how neurosurgery and neurology can join forces to build something unique. In Gainesville, they built one of the most important DBS programs in the world, essentially from scratch, after setting their minds to this goal during residency. We talk the concepts behind the Think Tank, their work on the DBS Tourette's Disease registry, the importance of collaborations in the field and future / (present?) concepts such as adaptive DBS, their «tick detector» (about which we could already hear in episode #21 between Aysegul Gunduz and Julian Neumann) and the general future of the field.

In this episode, Dr. Michael Okun shares the latest in 2022 for new and emerging therapies for Parkinson's. For more information and related resources go to: http://davisphinneyfoundation.org/podcast-recording-new-treatments-and-therapies-parkinson's Visit www.dpf.org to discover more of what the Davis Phinney Foundation is doing today to help you LIVE WELL with Parkinson's.   

World Parkinson's leader, Dr. Michael Okun, shares his expertise and incredible perspective on the disease, how to best manage it, and its outlook in this wonderfully informative interview. Dr. Michael Okun is the Adelaide Lackner Professor and Chair of NeurologyExecutive Director, Norman Fixel Institute for Neurological Diseases at University of Florida Health

Larry & Rebecca Gifford dive deep in to deep brain stimulation (DBS). We learn about the innovative technology used for DBS from Dr. Alfonso Fasano, the chair of Neuromodulation and multi-disciplinary care at the University of Toronto and University Health Network. Sonia Soriano-Espert from Valencia, Spain, through translator and friend Sabela Avion, shares her experience of having DBS surgery conducted by a robot. This interview first aired on ODNA PK radio in Spain. The hosts are PD Avengers and members of Con P de Parkinson, a growing group of women who speak Spanish and have PD. In part-one of this two-part arc, Heather Kennedy and Becca Miller were preparing for DBS Surgery. In part two, both women share their surgery experience. The share how their children responded and how they feel about DBS, now that they have had it.  Thank you for listening.  Send us songs you would want to listen to while undergoing DBS.   EMAIL US: ParkinsonsPod@CuriousCast.ca  Or add the songs you'd want to listen to during DBS to the WLGYP DBS PLAYLIST on Spotify Have questions for Larry & Rebecca? Do you want to share your DBS story or have an idea for an upcoming podcast? Want to share how the podcast has helped you? Click the link on your laptop or desktop and leave us a voice message.https://www.speakpipe.com/WhenLifeGivesYouParkinsons Follow us, Larry & Rebecca Gifford  Twitter: @ParkinsonsPod Facebook: Facebook.com/ParkinsonsPod Instagram: @parkinsonspod Thank you to the following people and organizations featured in this episode: Alfonso Fasano, MD, PhD, Chair in Neuromodulation and Multi-Disciplinary Care, Neurologist, Co-Director of the Surgical Program, Movement Disorders Centre, Toronto Western Hospital.   Heather Kennedy, PwP, WPC2023 Ambassador a.k.a. Kathleen Kiddo Becca Miller, PhD, PwP, Michael J. Fox Foundation Patient Council, Assistant Professor of Psychiatry at Yale University.  Michael S. Okun, MDUniversity of Florida Kelly D. Foote, MD University of Florida Ted X Talk about DBS from Michael Okun, MD and Kelly Foote, MD (2012) Sonia Soriano-Espert, PwP, Valencia, Spain. Con P de Parkinson Sabela Avion, PwP, NYC & Spain. Founder of Parkinsonic. Con P de Parkinson Special music acknowledgements. Thank you to Justin Timberlake. We played 12 seconds of “Cant Stop The Feeling!” Credit goes to the song writers Timberlake, Max Martin, and Johan Schuster. Timberlake and Martin are also credited as producers along with Shellback.   Thank you to Taylor Swift. We played :17 of “Shake it Off.” The song was written by Swift, Max Martin and Shellback. It was released on Big Machine records in 2014. A special thanks to Dorothy and Scarecrow. “If I Only Had a Brain,” is heard for 31 seconds. The song is featured in the 1938 film The Wizard of Oz. It is written by Harold Arlen and Yip Harburg. Ray Bolger and Judy Garland sang it when their characters first met along the yellow brick road. The film is still under copyright by Warner Pictures. Our Promotional Partners include:   Diagnosed with Parkinson's? You are not alone. Contact presenting partner Parkinson Canada http://www.parkinson.ca/, call the toll free hotline 1-800-565-3000 or on Twitter you can message @ParkinsonCanada. Here is a link to Parkinson Canada's “Together: No Matter What” campaign Thanks also to our content and promotional partners The Michael J. Fox Foundation Parkinson's Podcast hosted by Larry Gifford Spotlight YOPD – The only Parkinson's organization dedicated to raising awareness for Young Onset Parkinson's disease and funds for the Cure Parkinson's Trust.   PD Avengers –  We are building a global alliance to end Parkinson's. Join us. World Parkinson Congress 2023 –Make plans to join us for #WPC2023 in Barcelona, Spain. Credits Dila Velazquez – Story Producer Greg Schott – Sound Design See omnystudio.com/listener for privacy information.

Drs. Ray Dorsey and Michael Okun, both leading experts in the United States on parkinson's disease, have a prescription for action on how to prevent the disease in the first place and offer revolutionary treatment for those suffering. This week, they are speaking with Next Steps Forward host Chris Meek about their book “Ending Parkinson's Disease: A Prescription for Action” and their PACT initiative. They will break down step-by-step what PACT is composed of: P - Prevent the disease, A - Advocate for protective policies, C - Care for patients, and T - Treat the condition with innovative therapies, and how even average citizens can play a part in ending the disease by making the commitment to carry out the steps of PACT themselves. With a bold vision on how to eventually prevent the disease altogether, Drs. Dorsey and Okun explain to the audience what it would take to get there - medically, financially, politically and socially. Whether you are a patient, relative of someone living with the disease, clinician, politician or activist, this hour has imperative and life changing information in store for you.

Drs. Ray Dorsey and Michael Okun, both leading experts in the United States on parkinson's disease, have a prescription for action on how to prevent the disease in the first place and offer revolutionary treatment for those suffering. This week, they are speaking with Next Steps Forward host Chris Meek about their book “Ending Parkinson's Disease: A Prescription for Action” and their PACT initiative. They will break down step-by-step what PACT is composed of: P - Prevent the disease, A - Advocate for protective policies, C - Care for patients, and T - Treat the condition with innovative therapies, and how even average citizens can play a part in ending the disease by making the commitment to carry out the steps of PACT themselves. With a bold vision on how to eventually prevent the disease altogether, Drs. Dorsey and Okun explain to the audience what it would take to get there - medically, financially, politically and socially. Whether you are a patient, relative of someone living with the disease, clinician, politician or activist, this hour has imperative and life changing information in store for you.

Larry & Rebecca Gifford dive deep in to deep brain stimulation (DBS). We challenge the Neuroscience perception that the brain is everything we know and do, and everything we are. We believe, more than just a brain that makes us human, empathetic, and real.  This first part prepares you for the surgery. We call it DBS 101. We will explain terminology detail the lead up to the surgery, and tell you why it matters where the lead wires are placed in your brain. We explore our personal hesitations surrounding DBS. And we revisit friends of the podcast, Heather Kennedy and Becca Miller, both of whom are recovering from recent DBS surgeries.  Thank you for listening. Add your voice to the show and leave a message for us here; https://www.speakpipe.com/WhenLifeGivesYouParkinsons   Follow us, Larry & Rebecca Gifford  Twitter: @ParkinsonsPod Facebook: Facebook.com/ParkinsonsPod Instagram: @parkinsonspod   Thank you to the following people and organizations featured in this episode: Heather Kennedy, PwP, WPC2023 Ambassador a.k.a. Kathleen Kiddo Becca Miller, PhD, PwP, Michael J. Fox Foundation Patient Council, Assistant Professor of Psychiatry at Yale University.  Michael S. Okun, MD University of Florida Kelly D. Foote, MD University of Florida Ted X Talk about DBS from Michael Okun, MD and Kelly Foote, MD (2012) Diagnosed with Parkinson's? You are not alone. Contact presenting partner Parkinson Canada http://www.parkinson.ca/, call the toll free hotline 1-800-565-3000 or on Twitter you can message @ParkinsonCanada. Here is a link to Parkinson Canada's “Together: No Matter What” campaign Thanks also to our content and promotional partners The Michael J. Fox Foundation Parkinson's Podcast hosted by Larry Gifford Spotlight YOPD – The only Parkinson's organization dedicated to raising awareness for Young Onset Parkinson's disease and funds for the Cure Parkinson's Trust.   PD Avengers –  We are building a global alliance to end Parkinson's. Join us. World Parkinson Congress 2023 –Make plans to join us for #WPC2023 in Barcelona, Spain. Credits Dila Velazquez – Story Producer Greg Schott – Sound Design See omnystudio.com/listener for privacy information.

Today on Meldon Law & Friends, we are joined first by Dr. Michael Okun, the chair for the UF Health Department of Neurology and the Executive Director of Norman Fixel Institute for Neurological Diseases at UF Health. He is the world's leading expert in Parkinson's disease & Dystonia and has been behind the research for Tyler's Hope for over 15 years. He was also one of Muhammad Ali's doctors.  Our second guests are Lizzie Jenkins of the Real Rosewood Foundation and Melody Vaughn, owner of Melody Vaughn Interiors. Lizzie Jenkins and Melody Vaughn are working on rebuilding and remodeling some of Rosewood, Florida. They will tell us more about the Rosewood Massacre, why they are rebuilding Rosewood, and more about Melody Vaughn Interiors. We look forward to seeing you LIVE at 1:00 PM ET and encourage your questions for our guests!

We talk with Dr. Robert Okun about Ending Parkinson's Disease: A Prescription for Action. And Lionel Shriver talks about Should We Stay Or Should We Go. The post Dr. Michael Okun, ENDING PARKINSON’S DISEASE & Lionel Shriver, SHOULD WE STAY OR SHOULD WE GO appeared first on Writer's Voice.

Today's interview is with Dr. Ray Dorsey and Dr. Michael Okun who co-wrote the book with Todd Sherer, Ph.D., and Bastiaan R. Bloem, MD, Ph.D. This book is A PRESCRIPTION for ACTION ENDING PARKINSON'S DISEASE Dr. Dorsey and Dr.Okun discuss why we must increase funding to find a cure, why the book was written. We also discussed how the environment plays a role in developing PARKINSON'S DISEASE. This book is an eye-opener and Betsy highly recommends reading this book For more information and contact on this subject: https://bit.ly/3bvgV9d Learn more about your ad choices. Visit megaphone.fm/adchoices

Today’s interview is with Dr. Ray Dorsey and Dr. Michael Okun who co-wrote the book with Todd Sherer, Ph.D., and Bastiaan R. Bloem, MD, Ph.D.This book is A PRESCRIPTION for ACTION ENDING PARKINSON’S DISEASEDr. Dorsey and Dr.Okun discuss why we must increase funding to find a cure, why the book was written. We also discussed how the environment plays a role in developing PARKINSON’S DISEASE. This book is an eye-opener and Betsy highly recommends reading this bookFor more information and contact on this subject: https://bit.ly/3bvgV9d

PARKINSON’S DISEASE IS THE WORLD’S FASTEST GROWING NEUROLOGICAL DISORDER AND SOME EXPERTS ARE CALLING FOR AN “OPERATION WARP SPEED”-TYPE COMMITMENT TO DEVELOPING A VACCINE. JOINING US TO DISCUSS IS DR. MICHAEL OKUN, MEDICAL DIRECTOR OF THE PARKINSON’S FOUNDATION AND CO-AUTHOR OF THE BOOK: “ENDING PARKINSON’S DISEASE”.

The fight for a cure to Parkinson’s Disease has been a decades-long battle, with several treatments evolving alongside the evolution of medicine as a practice. In this episode, host Richard Miles sits down with Dr. Michael Okun, the Chair of Neurology, and Professor and Executive Director of the Norman Fixel Institute for Neurological Diseases at the University of Florida College of Medicine. He is an expert on deep brain stimulation, and author of over 400 peer reviewed articles as well as the book Parkinson’s Treatment: 10 Secrets to a Happier Life. Here, Dr. Okun dispels myths surrounding Parkinson’s, talks about his research and clinical work, and discusses his involvement with several non-profits raising awareness on other conditions and diseases. “Every day that I practice medicine, I know less,” says Dr. Okun. “It’s a profession where you have to have a lot of humility. You have to have an open mind and things change over time.” TRANSCRIPT: Intro (00:01): Inventors and their inventions. Welcome to Radio Cade, a podcast from the Cade Museum for Creativity and Invention in Gainesville, Florida. The museum is named after James Robert Cade, who invented Gatorade in 1965. My name is Richard Miles. We’ll introduce you to inventors and the things that motivate them, we’ll learn about their personal stories, how their inventions work and how their ideas get from the laboratory to the marketplace. Parkinson’s Disease. What do we know about it? Why does it seem to be more common and how do we treat it? Welcome to Radio Cade. I’m your host Richard Miles today. I’m pleased to welcome Dr. Michael Okun the Chair of Neurology and Professor and Executive Director of the Norman Fixel Institute for Neurological Diseases at the University of Florida College of Medicine. Dr. Okun’s also an expert on deep brain stimulation and author of over 400 peer-reviewed articles, as well as the book “Parkinson’s Treatment: 10 Secrets to a Happier Life.” Welcome to Radio Cade, Dr. Okun. Dr. Michael Okun (01:11): My pleasure to be here, Richard. Richard Miles (01:12): So before we start, I have to mention you’re also a poet and that caught my eye mostly because I find myself in middle age becoming very interested in poetry, but only as a reader, not an actual poet. So I have to start, is this something you’ve always done or is it because being a brain doctor wasn’t challenging enough for you? What got you into poetry? Dr. Michael Okun (01:28): My original bent was in humanities, and I have a degree in history. And so, I love to write, and I love to try to express myself in different ways. I love poetry, because there’s a new precision towards, and I think that through poetry, you can express concepts using emotions and other modalities to reach your readers. And so, over the years I’ve done a number of poems, and I have an old book called “Lessons From the Bedside” and have done some writings in said time as well. Richard Miles (02:01): I love that analogy too, to the work that you do. Cause one of the things I have noticed in my very limited foray into studying poetry is precisely what you said, that the precision of the use of certain words versus not other words. And that reveals a lot of the thinking and so on. And I imagine studying medicine, there is some similarities there. Dr. Michael Okun (02:18): That’s right, and really keeping an open mind. And I am also a neurologist by training. And so I practice medicine and I say often that every day that I practice medicine, I know less. It’s a profession where you have to have a lot of humility. You have to have an open mind and things change over time. And we’re really like cabinet advisors to people. We’re here to help with the best information that we can, but we really shouldn’t be so prescriptive, and so sure of ourselves. And I think anybody, whether you’re an inventor, you’re a scientist, you’re a clinician or all of the above, will look back and say what I did five years ago, versus what I’m doing now, is different. And it might seem subtle because you lived it, but if you think in those terms, that’s, I think what I would term as wisdom and you realize that practice of medicine and the understanding of diseases evolves and that there’s not one solution for everyone. Richard Miles (03:15): That’s a great way of looking at it. And that really helps, I think, for what we’re about to talk about now, and that is you have developed, or you’re known as really one of the world’s experts on a technique to treat Parkinson’s. But before we get into the details of what that is and how it works, I’d like to talk more broadly about Parkinson’s itself, which is a disease that most people probably have heard of or know somebody with Parkinson’s, but they may not know exactly how it works and what are some of the underlying causes. And I noticed that a few years ago, you wrote a paper called “The Emerging Evidence of the Parkinson Pandemic,” which caught my eye, obviously because we’re in the midst of another pandemic. And so pandemics in general, I think are of higher interest to everyone. But in that paper, you said that neurological disorders are now the leading source of disability globally, and the fastest growing neurological disorder in the world is Parkinson’s disease. And you said that from 1990 to 2015, so about a quarter century time period, the number of people with Parkinson’s disease doubled to over 6 million. And finally your quote, “for most of human history, Parkinson has been a rare disorder, but various factors have now created” what you call Parkinson’s pandemic. There’s a lot there, but why don’t we start by briefly describing for listeners who are maybe not exactly sure how Parkinson’s differs from other types of neurological diseases. Define it for us. And then why don’t we spend some time talking about those various factors that have caused it apparently to go from a rare condition to pandemic-level proportions. Dr. Michael Okun (04:40): So first Parkinson’s Disease, it’s a neurological syndrome, and it comes with symptoms that people can readily detect. Oftentimes when you’re in a crowd, you see somebody might be shaking, they might be shuffling their feet, their handwriting might be small when they’re at the bank, and they may be struggling with some of these, what we call motor features and also what we call non-motor features. So it’s a brain disease that affect depression, anxiety, and quality of life. And it turns out that Parkinson’s Disease is not just a disease of dopamine. And so a lot of people believe that you lose dopamine in the brain and you get Parkinson’s, it’s actually degeneration of multiple circuits. I’ve spent my career studying the circuits and Parkinson and in other diseases. And when we think of Parkinson, I remember when I was at the White House in 2015, I was quoted as saying, “Parkinson is,” and I’m not the first person that said this and won’t be the last, “the most complex medical disorder period,” because there’s over 20 motor features and non-motor features. So tremor, stiffness, slowness, (and not everybody gets tremors and not everybody gets stiff necessarily, it could be different varieties) in depression, anxiety, sexual dysfunction, other issues too. And then you throw in dopamine replacement therapies, you throw in deep brain stimulation ,what you mentioned, and it’s something that we’ve been researching now for a few decades here at University of Florida with one of my partners, Kelly Foote, and Mendez and many other people in the laboratory. And so Parkinson’s Disease is a neurological disorder. It is rapidly expanding. And about eight years ago in the book, 10 Secrets to a Happier Life, in the prologue, I said: “Parkinson has all the same characteristics of a pandemic.” And that was very controversial at the time. That’s eight years ago. And our most recent book that just came out from Hatchette publishing, “Ending Parkinson’s Disease,” it was originally titled the Parkinson’s pandemic. The publisher changed the title, and they wished they could have that back because it came out in March, 2020. So, “pan” means “all” in Greek, “demos” means “people.” And when you apply the concepts of a pandemic, they can apply to other diseases. Although, I was just on a call with the World Health Organization last week, and I think it’s fair to keep the term pandemic reserved for infectious diseases. Although people should know that the rapid expansion, the geography, the people not being immune to it, it all applies to other diseases like Parkinson’s. Richard Miles (07:06): So tell us, what are some of the factors that researchers have uncovered, or maybe that you hypothesized are at work here that are causing it to grow, I’m guessing, dramatically on a per capita basis? Are there geographic differences, for instance, in range between different countries or different demographic groups? What is going on here, and what do you think is behind it? Dr. Michael Okun (07:25): So we just had a conference with our colleagues in Geneva, Switzerland at the World Health Organization that have taken this on. And there’s a working group of us from all different countries, from rich countries, from poor countries, from countries somewhere in the middle…Parkinson occurs in all of the above. Now, one of the myths of Parkinson is that it’s all due to aging. And so as you get older, you get a higher prevalence of Parkinson and that’s true. Now, many people might be surprised when I tell you in our waiting room, I see people in their teens, and twenties and thirties with Parkinson’s, and it becomes more of a common as you get older, but it doesn’t mean it can’t occur in young people, as well as people–I don’t say old people–I say more seasoned people. And it turns out that age, it’s a myth. Age is not the only thing that’s driving this increase. There is going to be a doubling of Parkinson between 1990 and 2015. That’s already happened. It’s going to double again from 2015 to 2040 and could collapse healthcare systems, cause lots of suffering if we don’t get out in front of it. And so there are other factors that are driving this. And one of the ones that we talked about in the latest book is about pesticides and chemicals and environmental factors, and how those factors and the industrialization of society and how that’s changed the game. Richard Miles (08:47): That’s fascinating. So let’s move on to, what are some of the treatments that are available? You mentioned deep brain stimulation that you and Dr. Foote and others have been working on for a couple of decades. What led you to that I guess, and tell us how it works and what sort of improvements that you see? Dr. Michael Okun (09:02): Back in the 1930s and 40s, there weren’t treatments for Parkinson’s and for other diseases of movement. Some of the early attempts were actually making holes in people’s minds and disrupting these abnormal conversations. So if we think of the brain as a group of islands and the islands are all talking to each other, if you disrupt the conversation, people discovered that this is a potential way to treat specific symptoms, depending on which circuit you disrupt that conversation. And as time evolved, we were able to modulate conversations by using medicines. And the first major medicine was introduced by George Cotzias in the 1960s, and that was dopamine replacement therapy. And that actually modulates, it changes the way the brain’s oscillations are moving, and everybody, whether you’re awake or you’re asleep, your brain is always oscillating. And when you have a disease, particularly in neurological disease, that oscillates in different ways. So surgeries came back; when we have better technology to get to very specific sub millimeter zones of the brain, we started burning out pieces of the brain and that’s what I did during my training. And then as we moved along, we began to understand how the different areas were talking to each other, and we develop what’s called neuromodulation, so sticking straws in, introducing electricity into those circuits, I’m trying to change the way that they would talk to each other. And so my mentor and one of Kelly Foote’s mentors who I work with is a man named Mahlon DeLong at Emory University. He’s retired now, but a tremendous human being, and he was the one that really spent years and years at the National Institute of Health, and then at Hopkins, and at Emory decoding what the circuits are. And in 2015, he received the Lasker Award, which is one of the highest awards in medicine, just under the Nobel, for this work. Richard Miles (10:50): Doctor, now that this is becoming more common and will become more common, walk us through what happens when, let’s say someone’s parent they’re 60, 65, 70 years old, they’re brought in to a doctor like you or a clinic somewhere, and they’re diagnosed with Parkinson’s. What are some of the first steps of treatment? And coming back to deep brain stimulation, is this a one and done type of treatment, or is this a continuous regimen of treatments over time? And then what does the outcome look like for, say, someone in their mid-fifties or early sixties? Dr. Michael Okun (11:20): So when we think about Parkinson’s Disease, the first thing we think about is when somebody comes in, we need to understand when you say those words, “you have Parkinson’s Disease,” it’s not the end of the world. Okay? There are a lot of different forms of Parkinson’s Disease. And I have folks in my practice I’ve taken care of for 20, 30, 40 years. Okay? So it’s important for us to dispel that myth. And as we dispel the myth and begin to deliver treatment, we recently wrote in the Lancer last week, a seminar on Parkinson’s Disease, 20 page-seminars, get your coffee if you want to read it. But we talk about, in that seminar, there’s a picture of when we started here at University of Florida, we had this concept of model for caring for the Parkinson person. And we said, the person’s the sun, and we should all orbit around the person and the family, because this is such a complex condition. And there are so many, you know, specialists; you need an archeologist, a neurosurgeon, neuropsychologist, PT, OT, and speech, or maybe you need a nutritionist, access to clinical trials… We have over a hundred clinical trials, it becomes confusing. And so, we need to integrate the care, and if we integrate the care into what we call a multidisciplinary team, we’ve learned that it isn’t just–I call myself the drug dealer as a neurologist. It isn’t just the drug dealer or the device dealer, where we take people to the operating room and put a device in that provides the best possible care. It’s this model of interdisciplinary care, and it continuously changes over time, and you have to actually listen to the people, so it’s a different specialty, and to actually listen to the clues that they give you on how they’re living in order to change timing and change doses. There’s over a dozen different medications, there’s all sorts of infusions, there’s deep brain stimulation. And I like to teach, and we have fellows here who, after they’re done with their neurology residency, spend two years with us to train in this, and we’ve trained about 70 of these were all over the world. And what I like to tell people is Parkinson is like a lifetime disease. Think of all these different therapies, and you need to understand how the disease evolves and when is the right window to apply each one. So deep brain stimulation isn’t for everyone at all times, but there are points in the treatment where it can provide extremely beneficial effects on things like just suppressing tremor or movements we call dyskinesia. And so knowing the disease and knowing the person, and then creating the right multidisciplinary plan is important. And the last point is, we wrote something for the Journal of the American Medical Association last year with Melissa Armstrong here at UF. And we, as experts said, a first-line therapy now is exercise. We now recognize that exercise is so beneficial for this disease, that it’s now considered a first-line therapy, right along with the medications. And so that should tell you something about the humility of treating this disease for so many years and us understanding what’s good for folks and what’s not. Richard Miles (14:18): If we compare this to a disease like cancer, is Parkinson’s something that could actually be put into remission, or is this a steadily degenerative disease? All the treatments are just slowing down or resting that trajectory, but essentially it’s going down, or can you stabilize somebody for a decade, for instance, with no decline? How does that compare to something like cancer? Dr. Michael Okun (14:37): Parkinson’s is a progressive neurodegenerative disorder. Now there are multiple what we call phenotypes. So we have what some people call benign Parkinson, because it progresses so slowly. And then there are other forms that progress faster. We’re just beginning–it’s like Genesis of the Bible–we’re just the in first couple of days in understanding actually the differences between some of these entities, but it is progressive. Now people might say, well, tell me, how did Pope John Paul get anointed as a Saint, right? Didn’t he cure a nun of Parkinson disease, and that’s how he achieved sainthood. Well, we’d like to leave that story alone because it turns out that many people who are presumed to have Parkinson’s disease do not. And so if you get better then you may not have Parkinson’s, and then there’s a group of people who have tremors and other symptoms that look like Parkinson’s. About 10%, about one in 10, very early on, when you first see them, then never progress. And a lot of times people don’t go back and realize, wait, this person’s not progressing at all — hey actually don’t have Parkinson, they have something else that’s more benign. And we realized that, and we gave this crazy name to that called scans without evidence of dopaminergic denervation. I would never call a person a sweat, that’s what it stands for. But, if you’re not progressing, you may not have Parkinson’s. And sometimes early on the diagnosis can be made in the wrong direction as well. And so it’s very important, but when you do have Parkinson right now, it’s progressive. Now we are searching for things that will slow the disease down and, or provide precision medicine or other treatments for it, but we haven’t gotten there yet. Richard Miles (16:15): So let me come back to something you just said about perhaps a faulty diagnosis. It sounds like the ideal treatment or regimen of treatment is this interdisciplinary approach, which you’ve got multiple people looking at it and working on it from different angles for a patient, but I’m guessing that that level of complexity of care is not available to everyone. Do you have to be next to, say a major research hospital, like University of Florida, or some major metropolitan area to get that kind of care? And if you’re not, and you’re in a rural area or in a very poor country, for instance, what is the outlook for somebody in their mid-sixties? Dr. Michael Okun (16:44): So in general, if you can get access to one of these multidisciplinary teams, it’s better. We know from Medicare data done by Allison Willis, who is at the University of Pennsylvania, that if you have access to even a neurologist, and most people don’t actually see a neurologist, if you have access to a neurologist, your morbidity and mortality, your nursing home placement, all of those things that are super important, those numbers get better. Just having access. If you have access to multidisciplinary care, the data is beginning to point that this is also better. There are centers of excellence that have been set up through foundations, ike I work as a medical advisor and former medical director for the Parkinson Foundation. We have 47 centers all over the globe, but these aren’t widely available to people. What we do at the University of Florida is we see people from all over the world, we always have, and we try to construct plans for them, so these plans can be carried out by people within local zip codes, whether your local zip code is in Australia or Asia, or you have flown in to be seen, you know, from there where we set the plans, and then we ask the therapists to follow them out. Beause a lot of therapists and other members of a multidisciplinary team, they may be giving you the wrong therapy. And sometimes the wrong therapy, Richard, is worse than no therapy in a disease like this. And so setting the right plans, communicating and creating public health value is important. And one of the three things, we just had a campaign it’s still ongoing called the Give a Dime for Parkinson’s Disease campaign, and our first goal was to get to 10,000 red cards to the White House. We’ve now reached 25,000. One of the three points, while we asked for three things– because if you ask for too many people get distracted–we’re asking the White House and congressional members to consider as one of the three things is to maintain telehealth access for people in the United States. That didn’t happen before COVID-19, and many people don’t realize that that’s not permanent. That has to be made permanent, and then we have to develop these types of interdisciplinary models, so that people who don’t have access or don’t live right next door can still get access and the right advice, and then put the right team together, so they can have the best outcomes. The best outcomes mean less falls, less fractures, billions of dollars in healthcare savings, happier people. And so I think it’s in everybody’s best interest, particularly as the disease has exploded. Richard Miles (19:06): And Dr. Okun, In addition to your research and your clinical work, I know you are involved in at least several nonprofits that I know of, probably more. Tell us a little bit about what you’re doing in those areas, like Tyler’s Hope and so on, and what has been the response as you’re trying to raise awareness on some of these conditions or diseases that are not as well known. Dr. Michael Okun (19:23): Yeah. So I think when you look at other diseases and what they’ve done to change the trajectory, the story of polio, the story of HIV, and in HIV, it took what we call four pillars to do that. So you have to develop a system with any of these nonprofits for any of these really important diseases that are going to affect society. P is for prevent, A is for advocate, C is for care, and T is for developing new treatments through research. We call it the PACT. So when we went and we researched, we said, what do you need to do? So we need to get all of our non-for-profits together and we need to organize and sum our voices, and reach that inflection point where we can become loud enough. We can advocate with enough force to actually push change. And that’s what happened in HIV. For example, they went from a few hundred million in funding to 3 billion, a year in funding. And now HIV, when I was an intern, my first year out of medical school, 25 years ago, this was a bad word to be on. If you have HIV, it was kind of the death word, and it was really not great. And now, it’s a chronic livable condition, the trajectory has changed for literally tens of thousands, if not more people, worldwide. And there’s a reason why that happened: prevent, advocate, care, and treat them. And advocacy was huge. And so I’m a big believer in non-for-profits and even more than opening the checkbook and writing the check, getting involved. And I’m a believer that when you sum voices together, if you can get to a certain level–and nobody knows exactly what that is, maybe we can ask them out loud while our tipping point lives through these things. But there is a moment where things tip. And so one of the things in Perkinson, for example, we’re trying to tip, one of the three things we’re asking for us increase the funding from 200 million to 2 billion a year, by 10 times, because we know that if you increase it by two times, you’re going to get twice as much research, twice as many young researchers. And so this is going to have a multiplicative effect. When it comes for Tyler’s Hope for just only a cure, here, this is a disease where we know the deletion. We know where it lives. We know quite a bit about it. We have a lot of technology, we just need to, sum our voices, push more money into this, and that’s what Tyler’s Hope is doing, push the advocacy, and we can create a precision medicine treatment. And I think we’re on our way and that disease as well, there’s still a way to go, but the same for Tourette. So I’ve been in the tourette world with a non-for-profit called the Tourette Association of America. So I think the story is the same, but I think part of the formula to reach impact is you have to bring together globally voices. And when we were speaking with World Health Organization, there were representatives from all countries talking about Parkinson and creating that grassroots movement. And we have a grassroots movement called the PD Avengers on Twitter. Now there’s 3000, like really loud, obnoxious people on one of them that are really making a lot of noise. And that’s what we need. We don’t need to be polite anymore. We need to be aggressive and charismatic and a bit obnoxious for these diseases. Richard Miles (22:26): I like how you put that and, as a comment, as an aside, I spent a good portion of my career overseas. And one thing that non-Americans are amazed by is the level for nonprofit activity that we have in the United States, directed towards all sorts of things, but in particular medicine or health, and the vibrancy of that sector really is something almost distinctly American. They obviously exist in other countries, but not nearly at the level and scope of what you see all over the place in small towns, big towns, and so on. Dr. Michael Okun (22:53): It’s a very special thing. And you’re absolutely right. I’ve done outreach to other countries. And I, I won’t say which country I was in, we actually brought some devices in and probably could have been arrested for doing that. And we were helping the doctors with some devices and some implants. And we were out seeing people all over, who just needed help. And it struck me in that experience, and I’ve seen it in other countries as well, that we helped a woman, and then they invited us to dinner, and we realized that, Oh my God, this woman that we helped is the mother of somebody huge in the country that has these huge business interests all over the country. And we said, why don’t you give a whole bunch of money to Parkinson’s disease? And they said, “give money to Parkinson disease? We don’t give money. This is an American thing.” You know, too, we’re having this discussion. “You all give away your money. We don’t do that. We don’t do charity.” And I thought, wow, it is really something special. And, and then I think they felt a little bit embarrassed. And then they said, well, we do give charity. But the charity we give is we support our sports teams. And so we explained to them, well, that’s not exactly charity. And so I do think that it is a uniquely American thing. It’s one of the things that differentiates us, makes us stronger and gives us the potential to mobilize and galvanize against diseases and other issues that face society. Richard Miles (24:12): And it’s also a perfect way to mediate between the individual who alone can’t do much, and the government, which often has a lot of resources, but is not terribly efficient in how it distributes them, so it creates this whole layer between small groups and very large governments. Dr. Okun, one final question or a couple of questions actually. At the Cade Museum, we like to not just tell a story of inventions, but the inventors, and not just the story of technology, but the researchers behind the technology. So tell us a little bit about pre-professional Michael Okun: what were you like as a kid? Did you know, early on you wanted to be a doctor or a researcher? What were some of your early influences? Dr. Michael Okun (24:48): Yeah, so I had it pretty good as a kid. I grew up with a good house. I had two parents. My father was a dentist, my mother was teacher. And so I kind of got left brain, right brain. They had very different ways of looking at the world. I was always memorizing things like the backs of baseball cards, statistics, things like that. And my life I’ve always had a joy. I’ve always been a person that’s had pure joy to be part of things. And so for me, a lot of my joy was in reading history and humanities and things like that. And so I saw myself more as a teacher and a teacher of history and even going into medicine for me, I saw myself as a black bag family practice doc. But what happened to me was life as a journey. And it’s like a lot of Chinese philosophers say, Lu Zhen is a famous Chinese philosopher who talks about roads, and there are no roads, and when there are no roads, a road is formed because people walk on that road. And so you walk your journey and you take your opportunities. And sometimes you don’t know exactly what you’re interested in or not interested in. And so even when I ended up saying, I want to go to medical school now and try to help people in underserved communities, I couldn’t tell you the difference between a neurologist and neurosurgeon you know, at that point in my life, and you just keep walking the road, and it turns out I’ve always been fascinated by people with tremors and movements and saying why. And I said, I would never do research. I’m a teacher. I would never do research. And then I realized that the government will give you a whole bunch of money to study things that you’re super passionate about that can help people. And so I was super passionate about figuring out where in the brain ticks came from. And so I’ve spent 20 years working on that problem, and we’ve developed devices, systems and things to try to address that problem, same with Parkinson and tremors and certain movements and funny walks. And so I’ve always been fascinated by that. I think the secret is, you find your passion, you spend as many minutes as you can doing your passion. And if you can get somebody to actually pay you to do it, then that’s the bonus, but the bonus doesn’t always happen. And I think in my life, all of those things have aligned and I have great joy every day that I come to work ,every day that we go to the operating room, Kelly and I, I have great joy. We’re always thinking, we’re always innovating. And we consider our labs a continuous beta test. We’re always writing papers. We’re always thinking about stuff. Now, one thing we’re not for people that are listening to this podcast, we’re not like business entrepreneurs. So we patented a whole bunch of different things: how you do a cap on this, how you do reporting on that, how a device would do this, how one side might turn this side on. And, we get involved with all of these things–vaccines–but our job is we just keep innovating, and then we hand that over to someone else and innovations square and let other people run with it, because our passion and our impact is trying to help as many people as we can. And so there are various different aspects to the creativity process, to the invention and the innovation process. And we have kind of a human laboratory, you know, in the operating room and in the clinics and in seeing people and they tell us what the problems are and we try to innovate for them. And the next steps happen as we try to create that, we try to write it down. Remember I like to write poetry and other things. We try to write it down and tell people what we did, and then the next steps will happen. So there is this beautiful process of innovation that happens, and there are a lot of people that quietly do that in the background like Kelly Foote and groups here that are just quietly doing their jobs, writing down what they’re doing, and then letting other people take it to the next level and commercialize these things and make sure that they get out there to help people. And there’s a great quote, I think it was Jonas Salk who they said, are you going to patent polio vaccine? And he said, well, that would be like patenting the sun. And so we’re all into patents and innovations and everything. But at the end of the day, we have a certain amount of minutes on the planet, and if we can come up with innovations that are going to help and impact people’s lives, I think that’s what most of the people, at least on the medical disease side of innovation, are interested in. And so you asked me what my message would be for kids or young people would just be follow your road, spend as many minutes doing the passion that you can, impact as many lives as you can. Don’t worry about the money. Don’t worry about that. Just worry about how much joy you have in your heart. That’s all you need to do. Richard Miles (29:14): That’s a great answer. And whether intentionally or not, you summarized also a good chunk of the origin story of the Cade Museum and Dr. Robert Cade, who invented as you know, Gatorade, because he didn’t have any idea how to take that product to market. He liked to write poetry. He had just a real joy in life for helping others and to his final day, he and his co-inventors, the number one thing they were proudest about, about Gatorade, was the fact that it became the cheapest and most widely available treatment for infant diarrhea in the third world. Wasn’t intended to do that, but that’s what they are really the proudest to have, not that it became a culture or a sports icon. And so it’s nice to hear you say that, but just in different words. Dr. Michael Okun (29:50): I think it’s a great story, and one I hope kids are listening to, but so many people will give you advice about your career and everything, and I think they make it more complicated than it needs to be. Richard Miles (30:01): You precluded my last question, was what would your career advice be? And you just gave it to me anyway, but it’s great advice and really appreciate having you on the show. You’re doing tremendous work, keep doing it. It’s inspiration on all sorts of different levels and wish you the best of luck. Dr. Michael Okun (30:13): It’s my pleasure, and we love the Cade Museum. We talked about being involved in non-for-profits, my wife and I are involved in, and we think it’s just a great thing for not only this community, but for the world. So thanks for all you do. Outro (30:25): Thank you. Radio Cade is produced by the Cade museum for creativity and invention located in Gainesville, Florida. Richard Miles is the podcast host and Ellie, Tom coordinates, inventor interviews, podcasts are recorded at Heartwood, soundstage and edited and mixed by Bob McPeak. The radio Cade theme song was produced and performed by Tracy Collins and features violinist Jacob Lawson.

The fight for a cure to Parkinson's Disease has been a decades-long battle, with several treatments evolving alongside the evolution of medicine as a practice. In this episode, host Richard Miles sits down with Dr. Michael Okun, the Chair of Neurology, and Professor and Executive Director of the Norman Fixel Institute for Neurological Diseases at the University of Florida College of Medicine.  He is an expert on deep brain stimulation, and author of over 400 peer reviewed articles as well as the book Parkinson’s Treatment: 10 Secrets to a Happier Life.  Here, Dr. Okun dispels myths surrounding Parkinson's, talks about his research and clinical work, and discusses his involvement with several non-profits raising awareness on other conditions and diseases.  "Every day that I practice medicine, I know less," says Dr. Okun.  "It's a profession where you have to have a lot of humility. You have to have an open mind and things change over time." 

Dr Michael Okun: Parkinson´s Disease with TRE´s Selina MacKenzie

Have Parkinson's? Know anyone with Parkinson's? PD information -Parkinson's is the fastest growing Neurological Disease in the world, yes even faster than Alzheimer's -1 out of 15 people will be diagnosed with PD -Parkinson's is the 14th leading cause of death in the Unite States -100 people will die daily with PD daily in the United States -200 people will be diagnosed daily with daily in the United States -The explosion in PD diagnosis is on target to bankrupt Medicare -Parkinson's is mostly PREVENTABLE??? Please listen to this show and/or buy the book "Ending Parkinson's Disease" All proceeds will go to Parkinson's charities